SHANGHAI, May 5 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that it has appointed Hao Zhou as Vice President of Finance.
Prior to joining WuXi PharmaTech, Mr. Zhou worked for eleven years at General Electric (NYSE: GE). He held positions of increasing responsibility in financial planning and analysis, enterprise resource planning (ERP) systems, accounting and internal control at GE and was based in Tokyo, London, Shanghai, and several locations in the United States. Most recently he was Finance Director, Greater China, for GE Medical Diagnostics and Life Sciences. He also served as an auditor for GE Corporate.
Mr. Zhou's responsibilities in his new role include financial planning and analysis, ERP system implementation, tax, and treasury. Christine Lu-Wong is named Vice President and Chief Accounting Officer and is responsible for financial reporting and accounting operations. Both Mr. Zhou and Ms. Lu-Wong will report to Edward Hu, Chief Operating Officer and Acting Chief Financial Officer of WuXi PharmaTech.
"I am very pleased to welcome Hao on board to ensure strong financial oversight of our company," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "With more than a decade of experience in a wide range of financial roles at a leading multinational company, including direct experience in healthcare and in the Chinese market, Hao brings us valuable hands-on expertise."
Mr. Zhou received his undergraduate degree in 1998 from Shanghai International Studies University, where he majored in English and Spanish language and literature.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
For more information, please contact: Sherry Shao (for the media) Tel: +86-21-5046-4002 Email: email@example.com Ronald Aldridge (for investors) Tel: +1-215-218-5515 Email: Ron_Aldridge@wuxiapptec.com
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved